echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Under the "battle" of the chemical drug market, these domestic enterprises are performing brightly

    Under the "battle" of the chemical drug market, these domestic enterprises are performing brightly

    • Last Update: 2020-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network Industry Dynamics: Chemical drugs are active ingredients extracted from natural minerals, plants and animals, as well as chemically or biosynthetic drugs, collectively referred to as chemical drugs.
    are special chemicals that are structurally defined to prevent, treat, diagnose diseases, or to regulate human function, improve quality of life, and maintain good health.
    public hospital drug market, these drugs sell well data show that in recent years, the public hospital drug market in key cities is showing a steady growth trend, sales in 2019 has been close to 180 billion yuan, the first half of 2020 due to the impact of the epidemic fell 17.33 percent, but sales are still more than 70 billion yuan.
    present, 70 billion market, from the market share of the top 20 manufacturers, domestic pharmaceutical companies have Yangzijiang, Qilu, Zhengda Tianqing, Shi Pharmaceuticals Andi Pharmaceuticals and other 8 enterprises to participate in the competition.
    in the top ten, although foreign pharmaceutical companies occupy the main seats, but domestic pharmaceutical companies also have Yangzijiang, Shenyang Sansheng, Shi medicine Baike 3 out of the breakout.
    Among them, Yangzijiang nervous system drugs, zosin injections accounted for 0.87% of the market share, Shenyang Sansheng Pharmaceuticals recombinant human platelet-producing hormone injections accounted for 0.64% of the market share, stone drug 100 grams of polyglycol recombinant human granulocyte stimulation factor injections also accounted for 0.54% of the market share.
    note that there have been some significant changes to the list compared to previous years.
    some of the best-selling drugs of the past, the market has fallen sharply.
    such as Roche known as the "troika" of curto-pearl mono-resistance, beval-pearl mono-resistance, lytoxi-mono-resistance due to the impact of bio-similar drugs, sales have fallen sharply.
    , beva bead monoantigen injections decreased by more than 10% YoY, while injections of terobethropoids and lytoxides decreased by more than 20% YoY.
    drug market under the impact of biological drugs, there is still an opportunity in recent years, with the consistent evaluation policy gradually clear, the continuous publication of the evaluation of preparations and new drug registration regulations to encourage innovative drugs to declare the market, the pharmaceutical injectables market is being affected.
    according to the Insight database, as of 17 April 2020, 255 varieties had passed/as follows been evaluated for generic consistency, of which only 33 were injectables.
    as a whole, the evaluation of chemical injections is not optimistic.
    But based on the leading position of injectables in the pharmaceutical market, the share of domestic chemical injections in 72% of injections, as well as the country has been promoting the quality and efficacy of chemical injection generics consistent evaluation work, the pharmaceutical injection market in the future will also appear many new market opportunities.
    industry believes that injections with the following characteristics will have greater prospects for development: First, in 2019 sales of more than 500 million yuan of injections of a single variety, such as zosin injections, injections of yew alcohol lipids and so on.
    second, china's list of participating preparations in 2019 sales of more than 300 million yuan, and consistent evaluation of the manufacturers of ≤3 varieties, such as injection of voliconazole, injection of retence and so on≤
    is that the U.S. is listed, China is not listed, and 2019 sales of more than $200 million varieties, such as injectable kaffezome, Regadsson injections and so on.
    , no matter which opportunity you choose, the result will still fall on the market competition.
    , the formulation of market strategy of pharmaceutical companies needs to change the traditional model of "market for the market" in the past, and the market strategy must be ahead of the way.
    the same time, the enterprise strategy also needs to be extended to the market operation accordingly, that is, the enterprise strategy and the market strategy should be highly integrated, in order to get out of a development path in line with the characteristics of the enterprise itself.
    if enterprises can comprehensively consider market conditions for the appropriate variety layout, will be a good opportunity to overstep the curve, not only to establish their own dominant position, but also for the development of domestic pharmaceutical industry to make more contributions.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.